Trevi Therapeutics (TRVI) Common Equity (2018 - 2026)

Trevi Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $172.1 million for Q1 2026.

• On a quarterly basis, Common Equity rose 73.07% year-over-year to $172.1 million in Q1 2026; TTM through Mar 2026 was $172.1 million, a 73.07% increase from a year earlier, with the FY2025 full-year figure at $183.2 million, up 83.9% from the prior year.
• Common Equity retreated to $172.1 million in Q1 2026 per TRVI's latest filing, from $183.2 million in the prior quarter.
• Across five years, Common Equity topped out at $198.5 million in Q2 2025 and bottomed at $10.5 million in Q1 2022.
• The 5-year median for Common Equity is $99.5 million (2025), against an average of $105.7 million.
• Across the five-year window, Common Equity sank 55.82% in 2022 and jumped 872.3% in 2023, its largest moves.
• Year by year, Common Equity stood at $107.5 million in 2022, then fell by 23.18% to $82.5 million in 2023, then gained by 20.71% to $99.6 million in 2024, then surged by 83.9% to $183.2 million in 2025, then fell by 6.07% to $172.1 million in 2026.
• Per Business Quant, the three latest TRVI Common Equity figures stand at $172.1 million (Q1 2026), $183.2 million (Q4 2025), and $189.8 million (Q3 2025).